Variation in the biochemical response to L-thyroxine therapy and relationship with peripheral thyroid hormone conversion efficiency

John E M Midgley, Rolf Larisch1, Johannes W Dietrich2,3 and Rudolf Hoermann1

North Lakes Clinical, 20 Wheatley Avenue, Ilkley LS29 8PT, UK
1Department of Nuclear Medicine, Klinikum Luedenscheid, Paulmannshoeher Strasse 14, D-58515 Luedenscheid, Germany
2Medical Department I, Endocrinology and Diabetology, Bergmannsheil University Hospitals, Ruhr University of Bochum, Buerkle-de-la-Camp-Platz 1, D-44789 Bochum, Germany
3Ruhr Center for Rare Diseases (CeSER), Ruhr University of Bochum and Witten/Herdecke University, Alexandrinistraße 5, D-44791 Bochum, Germany

Correspondence should be addressed to R Hoermann
Email rudolf.hoermann@gmail.com

Abstract

Several influences modulate biochemical responses to a weight-adjusted levothyroxine (L-T4) replacement dose. We conducted a secondary analysis of the relationship of L-T4 dose to TSH and free T3 (FT3), using a prospective observational study examining the interacting equilibria between thyroid parameters. We studied 353 patients on steady-state L-T4 replacement for autoimmune thyroiditis or after surgery for malignant or benign thyroid disease. Peripheral deiodinase activity was calculated as a measure of T4–T3 conversion efficiency. In euthyroid subjects, the median L-T4 dose was 1.3 μg/kg per day (interquartile range (IQR) 0.94, 1.60). The dose was independently associated with gender, age, aetiology and deiodinase activity (all \( P < 0.001 \)). Comparable FT3 levels required higher L-T4 doses in the carcinoma group (\( n = 143 \)), even after adjusting for different TSH levels. Euthyroid athyreotic thyroid carcinoma patients (\( n = 50 \)) received 1.57 μg/kg per day L-T4 (IQR 1.40, 1.69), compared to 1.19 μg/kg per day (0.85, 1.47) in autoimmune thyroiditis (\( P < 0.01 \), \( n = 76 \)) and 1.08 μg/kg per day (0.82, 1.44) in patients operated on for benign disease (\( P < 0.01 \), \( n = 80 \)). Stratifying patients by deiodinase activity categories of \(< 23\), \( 23–29 \) and \( \geq 29 \) nmol/s revealed an increasing FT3–FT4 dissociation; the poorest converters showed the lowest FT3 levels in spite of the highest dose and circulating FT4 (\( P < 0.001 \)). An L-T4-related FT3–TSH disjoint was also apparent; some patients with fully suppressed TSH failed to raise FT3 above the median level. These findings imply that thyroid hormone conversion efficiency is an important modulator of the biochemical response to L-T4; FT3 measurement may be an additional treatment target; and L-T4 dose escalation may have limited success to raise FT3 appropriately in some cases.

Key Words

- thyroid hormone replacement
- L-T4 therapy
- levothyroxine
- TSH
- triiodothyronine
- deiodinase
- conversion

Introduction

Thyroid disorders are among the most prevalent diseases in the western world, affecting as many as one out of seven adults (1). They are frequently associated with overt thyroid dysfunction, particularly various degrees of hypothyroidism that require thyroid hormone replacement (2, 3). This is mainly done by administration of
synthetic levothyroxine (l-T₄), which is a well-established, convenient, safe and inexpensive treatment modality (4, 5). However, this does not accurately reflect the natural direct secretion pattern of both thyroid hormones triiodothyronine (T₃) and thyroxine (T₄) by the thyroid gland (6, 7). Unlike other drugs, dosing of l-T₄ is not fixed but has to be titrated according to individual needs. Dose adequacy is mainly defined by reference to suitable biochemical standards, particularly thyrotropin (TSH) (8). This parameter has evolved into the main treatment target to be monitored and kept within an assumed euthyroid range (9). A number of studies have attempted to predict T₄ requirement, and various regimes for a starting dose have been proposed based on an average of 1.6 µg/kg body weight (BW) or by more refined weight- or BMI-related algorithms (10, 11, 12, 13, 14, 15, 16).

Although TSH measurement has dominated procedural management of thyroid replacement by its apparent ease and good standardisation, a disturbingly high proportion of patients remains unsatisfied with the treatment they receive (17, 18). This has prompted some authors including our group to question the validity of relying on the TSH level as the sole measure of dose adequacy in l-T₄-treated patients (19, 20, 21). We have shown that the homeostatic equilibria between TSH and peripheral thyroid hormones are modulated by various influences such as age, body mass and the treatment modality itself (22). As a controlling element, the effective TSH level derived in a healthy normal population cannot necessarily be inferred to be equally optimal for a given patient on l-T₄ medication, because the constitutive equilibria between TSH and thyroid hormones, especially FT₃, differ in health and disease (22).

In the present analysis, we examined the relationship of the l-T₄ dose with clinical categories and biochemical outcomes such as TSH, FT₄ and FT₃ levels. We sought to define the interaction between TSH and the FT₃ target and also to analyse the influences of modulators such as gender, age, disease category or the efficiency of T₃ conversion from T₄.

**Subjects and methods**

**Study design and objective**

An open prospective observational study (ClinicalTrials.gov NCT01969552) was conducted at the Department of Nuclear Medicine at Klinikum Luedenscheid, Germany, between July 2013 and February 2014 and approved by the Ethics Committee of the University of Muenster, Germany. Participants gave written informed consent.

The present secondary analysis is restricted to the subgroup of patients on steady l-T₄ treatment, examining dose requirements of l-T₄ including conditioning modulators, thyroid hormone conversion efficiency and relationships with biochemical outcomes such as TSH, FT₄ and FT₃ levels. The primary study outcome, namely the analysis of the interacting equilibria and interrelations between thyroid parameters under various conditioning influences such as gender, age and body mass and l-T₄ treatment has already been reported (22).

**Patients**

The original study involved 1912 adult patients who were consecutively seen, were free of severe comorbidity and provided written informed consent. For this subgroup analysis, 353 patients on thyroid hormone replacement meeting the following criteria were included: being seen as outpatients, presenting in a controlled functional state (FT₄ ≥10 pmol/l and TSH ≤4 mU/l) and having reached a steady state on a constant l-T₄ medication. Although infrequently seen in an ambulatory setting, patients with severe non-thyroidal illness or potentially interfering comorbidities were ineligible to participate in the study. This exclusion extended to other conditions and the use of comediations that may interfere with the resorption or measurement of thyroid hormones or with pituitary TSH. Patients with T₃/T₄ combination therapy (n=9), anti-thyroid drug use (n=99), hypothylastic/pituitary diseases (n=5) or pregnancy (n=3) were excluded before analysis.

Diagnostic procedures included a detailed history, physical examination, standardised questionnaire documenting gender, age, height, weight, smoking habits (75% answered), prior surgery or radiiodine treatment, thyroid medication (brand, dosage, duration, time of intake), other drugs, laboratory tests (FT₃, FT₄, TSH and, if autoimmune thyroiditis was suspected or to be excluded, thyroid peroxidase antibodies (TPO-Ab) or TSH-receptor antibodies (TSH-R Ab)) and thyroid imaging.

**Laboratory methods**

TSH, FT₃ and FT₄ were measured with an automated direct chemoluminescence method (Advia Centaur XP, Siemens Healthcare Diagnostics, Erlangen, Germany). TSH is traceable to the 3rd International Standard for TSH (WHO, IRP Nuclear Medicine at Klinikum Luedenscheid, Germany, NCT01969552) was conducted at the Department of Nuclear Medicine at Klinikum Luedenscheid, Germany, NCT01969552).
A TSH range from 0.006 to 160 mU/l was linear, and coefficient of variations of inter-assay imprecision ranged from 0.9% to 2.4%. Reference intervals were laboratory established and pre-evaluated for the local population, using 10–23 pmol/l for FT₄, 3.1–6.8 pmol/l for FT₃ and 0.4–4.0 mU/l for TSH (23).

TPO-Abs were determined by a competitive chemiluminescence method (ADVIA Centaur XP, Siemens Healthcare Diagnostics, reference range <60 U/ml) and TSH-R Abs by competitive ELISA (Euroimmun AG, Lübeck, Germany, reference range <2 U/l).

**FT₃–FT₄ ratio and calculated deiodinase activity**

As measures of conversion efficiency, we calculated the FT₃–FT₄ ratio by simple division of both parameters in pmol/l and the sum activity of peripheral deiodinases (SPINA-GD, termed ‘deiodinase activity,’ thereafter, nmol/s) from equilibrium levels of FT₄, FT₃ and estimated constant parameters for plasma protein binding, distribution and elimination with

\[
\tilde{G}_D = \frac{\beta_{31}(K_{M4} + (FT_4)(1 + K_{30}(TBG))(FT_3))}{\alpha_{31}(FT_4)} \text{ nmol/s}
\]

as previously described (20, 21, 24).

Although the two measures are closely related in the linear part of the substrate relationship defined by Michaelis-Menten kinetics, only the more complex formula \( G_D \) accounts for the saturation kinetics of the enzyme.

In addition to using estimated deiodinase activity as a continuous variable, we divided deiodinase activity in three distinct categories defining poor (<23 nmol/s), intermediate (23–29 nmol/s) or good (>29 nmol/s) converters. The cut-offs were pre-specified based on observations in L-T₄-treated patients vs healthy untreated converters. The cut-offs were pre-specified based on observations in L-T₄-treated patients vs healthy untreated converters. The cut-offs were 81/565). A TSH range from 0.006 to 160 mU/l was linear, and coefficient of variations of inter-assay imprecision ranged from 0.9% to 2.4%. Reference intervals were laboratory established and pre-evaluated for the local population, using 10–23 pmol/l for FT₄, 3.1–6.8 pmol/l for FT₃ and 0.4–4.0 mU/l for TSH (23).

TPO-Abs were determined by a competitive chemiluminescence method (ADVIA Centaur XP, Siemens Healthcare Diagnostics, reference range <60 U/ml) and TSH-R Abs by competitive ELISA (Euroimmun AG, Lübeck, Germany, reference range <2 U/l).

**FT₃–FT₄ ratio and calculated deiodinase activity**

As measures of conversion efficiency, we calculated the FT₃–FT₄ ratio by simple division of both parameters in pmol/l and the sum activity of peripheral deiodinases (SPINA-GD, termed ‘deiodinase activity,’ thereafter, nmol/s) from equilibrium levels of FT₄, FT₃ and estimated constant parameters for plasma protein binding, distribution and elimination with

\[
\tilde{G}_D = \frac{\beta_{31}(K_{M4} + (FT_4)(1 + K_{30}(TBG))(FT_3))}{\alpha_{31}(FT_4)} \text{ nmol/s}
\]

as previously described (20, 21, 24).

Although the two measures are closely related in the linear part of the substrate relationship defined by Michaelis-Menten kinetics, only the more complex formula \( G_D \) accounts for the saturation kinetics of the enzyme.

In addition to using estimated deiodinase activity as a continuous variable, we divided deiodinase activity in three distinct categories defining poor (<23 nmol/s), intermediate (23–29 nmol/s) or good (>29 nmol/s) converters. The cut-offs were pre-specified based on observations in L-T₄-treated patients vs healthy untreated subjects and in low (<2 U/l). As measures of conversion efficiency, we calculated the FT₃–FT₄ ratio by simple division of both parameters in pmol/l and the sum activity of peripheral deiodinases (SPINA-GD, termed ‘deiodinase activity,’ thereafter, nmol/s) from equilibrium levels of FT₄, FT₃ and estimated constant parameters for plasma protein binding, distribution and elimination with

\[
\tilde{G}_D = \frac{\beta_{31}(K_{M4} + (FT_4)(1 + K_{30}(TBG))(FT_3))}{\alpha_{31}(FT_4)} \text{ nmol/s}
\]

as previously described (20, 21, 24).

Although the two measures are closely related in the linear part of the substrate relationship defined by Michaelis-Menten kinetics, only the more complex formula \( G_D \) accounts for the saturation kinetics of the enzyme.

In addition to using estimated deiodinase activity as a continuous variable, we divided deiodinase activity in three distinct categories defining poor (<23 nmol/s), intermediate (23–29 nmol/s) or good (>29 nmol/s) converters. The cut-offs were pre-specified based on observations in L-T₄-treated patients vs healthy untreated subjects and in low (<5 ml) vs higher thyroid volumes (22). They approximate turning points in the relationship between deiodinase activity and FT₃, defining a central region with a derivative of about 0 and low or high regions with steeper slopes.

**Thyroid ultrasound and scintigraphy**

Thyroid volume was sonographically (10 MHz transducer) determined according to the ellipsoid formula. Reference values were <18 ml for females and <25 ml for males. A volume <1 ml was considered athyreotic. Larger nodules were further examined by scintigraphy.

**Statistical methods**

Descriptive data are reported as median plus interquartile range (IQR). We used Wilcoxon’s rank sum or a \( \chi^2 \) test in case of categorical variables for comparison of baseline characteristics. Correlations are based on Pearson’s product-moment when suitable or Kendall’s \( \tau \). Multiple variables and conditional influences were analysed by a generalised linear model (GLM) and approximated by a linear regression function over restricted intervals. \( \beta \) coefficients were derived from a linear model. TSH was used after logarithmic transformation. We tested for collinearity in the models using the variance inflation factor. A GLM with a binomial function (logistic regression) was used to assess success rates of the L-T₄ dose for reaching a TSH or FT₃ target and to create dose-related probability plots. Relative proportions were statistically compared by receiver operating characteristic curves and Delong’s test. \( P \) values <0.05 were considered significant for all tests. Statistical analyses were performed using Deducer (version 0.7-7) and the R statistical package (Mac version 3.1.2) (25, 26).

**Results**

The present analysis comprises 353 patients in a stable controlled non-hypothyroid state on thyroid hormone replacement with L-T₄. Patient characteristics are shown in Table 1. Of the total study group, 304 patients were euthyroid according to FT₄, 342 according to FT₃ and 216 according to TSH, based on their respective reference intervals with all displaying clinically satisfactory levels of medication.

Dose requirements associated with biochemical euthyroidism (n = 208) defined by the reference ranges of all three parameters varied widely from 25 to 275 µg/day L-T₄ (mean 98, median 100 (IQR 75, 125)) or 0.3 to 2.2 µg/kg BW per day (mean 1.2, median 1.3 (IQR 0.94, 1.60)). In univariate linear models, the L-T₄ dose in the treated euthyroid panel was significantly associated with gender, age, body mass index, aetiology of disease, T₃–T₄ ratio and calculated deiodinase activity (all \( P < 0.001 \)) but not with TSH (\( P = 0.94 \)). The influences remained independently predictive in a multivariable model (Table 2).

TSH levels in the euthyroid range were unrelated to any of the above influences except disease category (\( P = 0.003 \)), as might be expected considering the lower TSH target in malignant disease. Deiodinase activity was positively associated with thyroid volume (\( r = 0.23, Z = 4.39, P < 0.001 \)).

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
P<0.001, n=208) but inversely correlated with weight-adjusted L-T4 dose (r = -0.37, P<0.001, n=208).

In a biochemically defined euthyroid state excluding subclinically hyperthyroid subjects, athyreotic thyroid carcinoma patients received significantly higher doses of L-T4 (1.57 μg/kg BW per day (IQR 1.40, 1.69), n=50)) than patients with autoimmune thyroiditis (1.19 μg/kg BW per day (IQR 0.85, 1.47), n=76, P<0.001) or benign thyroid disease post surgery (1.08 μg/kg BW per day (IQR 0.82, 1.44), n=80, P<0.001)). Furthermore, after adjusting for differing levels of TSH suppression in a linear model the weight-adjusted L-T4 dose was higher in athyreotic carcinoma patients compared to autoimmune thyroiditis or benign disease (P<0.001, Fig. 1A). Similarly, the dose required to achieve the same FT3 concentration was higher in the carcinoma group (P<0.001, Fig. 1B).

Median thyroid volume was 0 ml (IQR 0, 0 ml) in carcinomas, 7 ml (IQR 4, 11 ml) in autoimmune thyroiditis and 6 ml (IQR 3, 8 ml) in benign goitre post surgery. The weight-adjusted L-T4 dose was inversely correlated with the thyroid volume in the three diagnostic groups (r = -0.22, P=0.002, n=208).

Three distinct categories of conversion efficiency were defined (see Subjects and methods) as follows: poor converters <23 nmol/s, intermediate converters 23–29 nmol/s and good converters >29 nmol/s deiodinase activity. The poor converters reached significantly (P<0.001) higher FT4 concentrations in the circulation than intermediate or good converters but, at the same time, showed significantly (P<0.001) lower absolute FT3 levels compared to the other two groups (Fig. 2). While the FT3–FT4 dissociation was apparent in all three disease entities, it was most pronounced in the carcinoma group (n=143, Fig. 2). The latter group showed the highest conversion efficiency.

### Table 1

**Characteristics of study group (n=353).** For referencing purpose, parameters in 146 disease-free individuals from the same study were as follows: median age 38 (26, 49) years, TSH 1.62 (1.12, 2.25) mU/l, FT3 5.0 (4.8, 5.2) pmol/l, FT4 14.0 (13.0,15.1) pmol/l, calculated deiodinase activity 32.8 (30.0, 36.2) nmol/s, thyroid volume 10 (8,13) ml (22).

| Parameter | Median (IQR) or percentage |
|-----------|---------------------------|
| Gender (female, male) | 280 (79%), 73 (21%) |
| Age (years) | 56 (46, 66) |
| In women vs men | 53 (45, 66) vs 59 (53, 64), P=0.03 |
| Disease aetiology (%) | Autoimmune thyroiditis 27%, Benign thyroid disease after surgery 32%, Thyroid carcinoma 41% |
| Surgery, radioiodine treatment (%) | 73%, 42% |
| BMI (kg/m²) | 27.5 (24.1, 30.8) |
| Dose (μg/day) | 100 (75, 150) |
| Weight-adjusted daily dose (μg/kg per day) | 1.47 (1.09, 1.72) |
| TSH (mU/l) | 0.64 (0.12, 1.47) |
| FT3 (pmol/l) | 4.80 (4.40, 5.30) |
| FT4 (pmol/l) | 18.6 (16.2, 21.1) |
| TPO-Ab (U/l) | 450 (48, 1300), positive 65%, n=97 |
| FT3–FT4 ratio | 0.26 (0.24, 0.29) |
| Thyroid volume (ml) – total group | 2 (0, 7) |
| Deiodinase activity (nmol/s) | 24.3 (21.8, 27.1) |
| Autoimmune thyroiditis | 7 (4,11) |
| Benign thyroid disease post surgery | 6 (2,10) |
| Thyroid carcinoma | 0 (0, 0) |

*82% of the thyroid carcinoma patients had a higher TNM stage than 1.  
*96% had no detectable residual thyroid volume by ultrasound after total thyroidectomy and radioiodine treatment.

### Table 2

**β coefficients in a linear model of covariates predicting dose of L-T4 in the euthyroid panel.** The multivariable model was simultaneously fitted with the parameters listed, all of which were significant predictors of the L-T4 dose in univariate models. All variance inflations factors were <1.2.

| Variable | β coefficient (95% CI) |
|----------|-----------------------|
| Gender male vs female | 0.22 (0.11, 0.33), P<0.001 |
| Disease aetiology | Autoimmune vs malignant disease -0.33 (-0.47, -0.19), P<0.001 |
| | Benign goitre vs malignant disease -0.34 (-0.48, -0.20), P<0.001 |
| | Age -0.26 (-0.37, -0.15), P<0.001 |
| | BMI 0.33 (0.22, 0.44), P<0.001 |
| | Deiodinase activity -0.27 (-0.39, -0.15), P<0.001 |

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The converter groups were similar (P > 0.1) in their age, BMI, weight-adjusted L-T4 dose and TSH levels except for men being overrepresented in the good converter group (P < 0.01).

Converter categories of the carcinoma group were comparable (P > 0.42) in their thyroid residual volumes, which were below 1 ml in 96% of all cases. In contrast, in the combined group of benign diseases the converter status was significantly associated with thyroid volume (4 (2, 8) vs 7 (4, 11) vs 8 (5, 12) ml, P = 0.009). Thyroid volumes differed between the carcinoma group and the benign diseases (P < 0.001) but not between autoimmune thyroiditis and goitre post surgery (P = 0.25, Table 1).

Figure 1
TSH (A) or FT3 (B) vs weight-adjusted L-T4 dose in three groups of patients on thyroid hormone replacement, with autoimmune thyroiditis (n = 96), after surgery for benign goitre (n = 111) or thyroid carcinoma (n = 143). Between group differences in both panels were significant (P < 0.01) and remained so after adjusting for volume (not shown, P < 0.01), as evidenced by linear models with the diagnostic group as a covariate. See text for further details. AIT, autoimmune thyroiditis; Goitre, goitre post surgery for benign nodular thyroid disease.

Figure 2
FT3 (A), FT4 (B) and TSH (C) levels in L-T4-treated patients stratified by disease and conversion efficiency. The disease entities were closely associated with categories of the thyroid volume (see Table 1 and text). The red box refers to poor converters (calculated deiodinase activity < 23 nmol/s), green to intermediate converters (deiodinase activity 23–29 nmol/s) and blue to good converters (deiodinase activity > 29 nmol/s). Remarkably, absolute FT3 concentrations were lowest in the poor converter group in all disease categories, while FT4 levels were highest in the poor converters. Wilcoxon test, revealed significant differences compared to each first group; *P < 0.05, **P < 0.001.

AIT, autoimmune thyroiditis; goitre, goitre post surgery for benign nodular thyroid disease.
A given weight-adjusted dose suppressed the TSH below the lower reference limit (<0.4 mU/l) in a higher proportion of carcinoma patients, than it raised their FT3 level above the median level typical of the euthyroid controls (>5 pmol/l) (Fig. 3A and B). Conversely, much lower doses reached a target of a fully suppressed TSH compared to the FT3 median (Fig. 3A and B). The same tendency is true for a more modest target below 1 mU/l for TSH in autoimmune thyroiditis or benign disease post surgery, although variation was higher in this panel (Fig. 3C and D). Overall, a significantly higher proportion of patients achieved TSH suppression compared to FT3 above median by Delong’s test employing receiver operating characteristic curves (P<0.001).

Discussion

In this cohort, dose requirements for l-T4-treated patients varied in a large euthyroid panel and were associated with many influences including gender, age, disease category and thyroid hormone conversion efficiency. However, not all of the treatment conditions necessarily aim at a biochemically euthyroid thyroid state as a comprehensive therapeutic goal, as defined by maintaining the respective reference ranges of all three parameters: TSH, FT4 and FT3. Particularly, in the treatment of thyroid carcinomas, for many patients in our sample the target was a lower or suppressed TSH below the reference range, which, as a consequence, raised FT4 levels above the upper reference range in a proportion of these patients. At both comparable levels of TSH suppression or similar FT3 concentrations, athyreotic thyroid carcinoma patients were taking a higher weight-adjusted dose of l-T4. Three remarkable and linked observations from this study were a dissociation between FT3 and FT4, an apparent disjoint between TSH and FT3 and an inverse association between l-T4 dose and conversion efficiency.

The present study was a cross-sectional secondary analysis not involving a randomised design. As previously reported in a separate communication (22), the primary aim of this prospective observational study was to analyse further the interacting equilibria. While introducing some uncontrolled variations, this allowed for the study of a broader natural spectrum of responses, as observed in consecutive patients. FT3 or FT4 measurements were not compromised in any way by problematic conditions such as the non-thyroid illness syndrome, as the study was conducted in a cohort of otherwise ‘healthy’ out-patients without relevant comorbidity. There was no evidence for a potential bias stemming from a variable time interval.
between i-T₄ intake and blood sampling, which might result in an expected slight temporary elevation of circulating FT₄ concentrations, as previously discussed (22). There were neither linear (P=0.27) nor non-linear (P=0.28) relationships with deiodinase activity.

In i-T₄ treatment, equilibria typical of the healthy state were found not to be invariant, but profoundly altered (22). Here we disclose further consequences that are associated with alterations in the regulatory patterns in patients under i-T₄ therapy. In particular, one aspect relates to the i-T₄ dose and conversion efficiency. We estimated T₄–T₃ conversion by calculating the sum activity of peripheral deiodinases (see Subjects and methods). The measure is similar to the FT₃–FT₄ ratio, albeit more precise wherein it accounts for non-linear enzyme saturation kinetics. However, it does not further differentiate global activity by type of deiodinase. Thus, the source of T₃ or contribution of various tissues to the T₃ plasma pool cannot be discerned. We found that a poor converter status was associated with a higher i-T₄ dose and higher serum FT₄ levels but still lower absolute FT₃ concentrations, compared to the more efficient converters. This paradoxically relates the higher T₄ supply to a worsened rather than improved absolute FT₃ level. This is not to say that an increasing dose will not raise on average the FT₃ but that the dose response varies widely among individuals, and conversion inefficiency in some patients may outweigh the dose effect in terms of achievable absolute FT₃ concentrations. How can this be explained? A high i-T₄ dose may not invariably remedy T₃ deficiency owing to T₄-induced conversion inefficiency but could actually hinder its attainment through the inhibitory actions of the substrate itself and/or reverse T₃ (rT₃) on deiodinase type 2 activity (27). A study by Cettour-Rose et al. (28) confirmed that rT₃, when infused into rats, inhibited deiodinase type 2 activity in the pituitary, cerebral cortex and brown adipose tissue, but interestingly, this did not have much impact on circulating T₄, T₃ and TSH concentrations in the animals. However, in this model the rT₃ effect was studied under rather artificial conditions in the absence of an abundant T₄ supply with elevated FT₄ levels that characterizes the treatment situation. In contrast, another recent experimental study has shown that escalating only the i-T₄ dose fails to normalize serum T₃ in the rat, and as a result, irrespective of local variations by type of deiodinase, all organs examined such as the brain, liver and skeletal muscle were hypothyroid at the tissue level in the presence of a normal serum TSH (29). This study suggests ubiquitination may be the limiting factor for T₄ alone to restore true tissue euthyroidism in the rodent (29). The lack of TSH stimulation and absence or functional deficiency of the thyroid gland may also impair T₄–T₃ conversion (30). Another important consideration is that, just as FT₄ and FT₃ dissociate under i-T₄ therapy, so do TSH and FT₃. While a high proportion of patients was able to achieve a target of a suppressed TSH below the lower reference limits or a TSH value <1 mU/l in autoimmune thyroiditis, their FT₃ levels at the same time frequently remained below the median FT₃ level found in normal subjects. The situation differs from conditions in which i-T₄ absorption may be impaired and, as a consequence, elevated TSH levels persist (31, 32, 33). Thus, not even an i-T₄ dose in which TSH is fully suppressed and FT₃ by far exceeds its upper reference limit can guarantee above average FT₃ levels in these patients, indicating an FT₃–TSH disjoint. As a consequence, although dose escalation may help some patients who maintained a sufficiently efficient thyroid hormone conversion to raise their FT₃ for euthyroidism and well-being, the strategy may not be invariably successful in all patients. In two studies, ~15% of athyreotic patients could not even raise their FT₃ above the lower reference limit on i-T₄ (19, 20). Another controlled follow-up study after hemithyroidectomy for benign euthyroid goitre suggests that this deficiency may have unwanted clinical consequences. In this study, weight gain after 2 years in association with a lowered thyroid function within the laboratory reference range was interpreted as a clinical manifestation of a permanently decreased metabolic rate (34).

i-T₄ dose requirements have been well studied and various regimes based on weight, BMI or more refined algorithms have been proposed to put patients on a presumed adequate dose from the very beginning (10, 11, 12, 13, 14, 15, 16, 35, 36, 37, 38, 39). As useful as these algorithms may be for average predictions and initial guidance in the general population, they do not take into account individual variations in the response to i-T₄ such as conversion efficiency. Dosing strategies solely based on a TSH definition of euthyroidism neglect the important role of FT₃, which has recently emerged as an equally significant parameter in defining thyroid physiology (20, 22, 29, 30, 40, 41). Central and peripheral regulatory mechanisms do not constitute divided levels of control, as has previously been assumed. Rather they are integrated via feed-forward control of deiodinase activity by TSH and operate jointly to maintain T₃ homeostasis as an overarching goal (30).
While acknowledging the role of genetically determined differences in deiodinase activity affecting conversion rates, the poor converter status described here appears to emerge mainly as a consequence of the T4 monotherapy itself, induced by the mechanisms discussed above (42, 43, 44, 45). Compared to untreated subjects, deiodinase activity and conversion efficiency tend to be diminished in i-T4 treatment (20, 22). However, individual pre-treatment measurements were not available for comparison. We found conversion inefficiency to be significantly correlated with low residual thyroid volume and most prevalent in athyreotic patients. However, differences in deiodinase activities were also apparent in the absence of a functioning thyroid gland within the group of thyroidectomised carcinoma patients. Overall, patients differ widely in the degree of the conversion impairment they suffer. This, in turn, may influence their dose requirements of i-T4 and, at a comparable weight-adjusted i-T4 dose, their levels of TSH suppression and circulating FT3 concentrations.

We speculate that i-T4-induced conversion inefficiency could prevent some vulnerable subjects from reaching true tissue normality on T4 monotherapy alone. Those were not analysed separately in the numerous earlier T3/T4 trials and could be possible candidates for a combined T3/T4 treatment option, as recognized by some authors and the guidelines of the European Thyroid Association (46, 47). As a limitation, this study addresses biochemical treatment responses but did not evaluate patient-reported outcomes or biomarkers of thyroid hormone action.

Whether conversion efficiency and the resulting differences in relationships between TSH, FT4 and FT3 are clinically useful markers of dosing inadequacy requires further well-designed prospective studies. Patient satisfaction, complaints and symptoms play an essential part in the clinical assessment. However, owing to considerable inter-individual variation, these measures apparently lack statistical power in a trial setting and have not been clearly linked to prognosis. For example, even a change in thyroid function as profound as the transition from the hypothyroid to the euthyroid state may be associated with only modest improvements in thyroid-related quality-of-life measures in patients with autoimmune thyroiditis (48).

As a result, a trial size of several thousand subjects may be required to produce a credible result with adequate discriminatory power. Additionally, the exact outcome would depend on the overall makeup of the panel as regards the mixture of T4–T3 conversion capabilities. Possible long-term consequences of the observed biochemical alterations such as the altered FT3–FT4 ratio are also presently unknown.

The findings of the present study have several clinical implications. First, they recognize thyroid hormone conversion efficiency, as defined by the calculated global deiodinase activity or more simply the T3–T4 ratio, is an important determinant of i-T4 dose requirements and the biochemical response to treatment. Second, in view of a T4-related FT3–TSH disjoint, FT3 measurement should be adopted as an additional treatment target. Third, in cases where an FT3–FT4 dissociation becomes increasingly apparent following dose escalation of i-T4, an alternate treatment modality, possibly T3/T4 combination therapy, should be considered, but further randomized controlled trials are required to assess the benefit versus risk in this particular group.

Declaration of interest
J W Dietrich is co-owner of the intellectual property rights for the patent 'System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual' (Singapore Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940). All other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements
The authors are grateful to Hans-Günther Wahl, Institute of Laboratory Medicine, Klinikum Lüdenscheid, for measuring thyroid hormones.

References
1 Bjoro T, Holmen J, Kruger O, Midthjell K, Hunstad K, Schreiner T, Sandnes I & Brochmann H. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trøndelag (HUNT). European Journal of Endocrinology 2000 143 639–647. (doi:10.1530/eje.0.1430639)
2 Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H & Tunbridge F. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clinical Endocrinology 1995 43 55–68. (doi:10.1111/j.1365-2265.1995.tb01894.x)
3 Roberts CGP & Ladenson PW. Hypothyroidism. Lancet 2004 363 793–803. (doi:10.1016/S0140-6736(04)15696-1)
4 Mandel SJ, Brent GA & Larsen PR. Levothyroxine therapy in patients with thyroid disease. Annals of Internal Medicine 1993 119 492–502. (doi:10.7326/0003-4819-119-6.199309150-00009)
5 Biondi B & Wartofsky L. Treatment with thyroid hormone. Endocrine Reviews 2014 35 433–512. (doi:10.1210/er.2013-1083)
6 Bianco AC, Salvatore D, Gereben B, Berry MJ & Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the thyroid hormones. *Endocrine Reviews* 2002 23 38–89. (doi:10.1210/edrv.23.1.0455)

7 Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F & Bianchi R. Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by multicompartamental analysis. *American Journal of Physiology. Endocrinology and Metabolism* 1990 258 E715–E726.

8 Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. *Thyroid* 2014 24 1670–1751. (doi:10.1089/thy.2014.0028)

9 Baloch ZW, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry J-F, LiVosli VA, Niccoli-Sire P, John R, uf J et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid* 2005 15 3–126. (doi:10.1089/thy.2005.15.3)

10 Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP & Berghout A. The association task force on thyroid hormone replacement. *Thyroid* 2014 34 205–230. (doi:10.1089/thy.2013.0661)

11 Toft Kristensen T, Larsen J, Pedersen PL, Feldthusen A-D, Ellervik C, Ford I, Højrup P, Laskarz E, Madsen M, Nørgaard M et al. Guidelines for the diagnosis and monitoring of thyroid disease. *Journal of Clinical Endocrinology and Metabolism* 2005 90 124–127. (doi:10.1210/jc.2004-1306)

12 Santini F, Pinchera A, Marsili A, Cecarini G, Castagna MG, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. *Journal of Clinical Endocrinology and Metabolism* 2005 90 2265–1720. (doi:10.1016/j.10028-09-0345-3)

13 Mistry D, Atkin S, Atkinson H, Gunasekaran S, Sylvester D, Rigby AS & England RJ. Predicting thyroxine requirements following total thyroidectomy. *Clinical Endocrinology* 2011 74 384–387. (doi:10.1111/j.1365-2265.2010.03940.x)

14 Jin J, Allemang MT & McHenry CR. Levothyroxine replacement dosage determination after thyroidectomy. *American Journal of Surgery* 2003 185 360–363 discussion 363–364. (doi:10.1016/j.amjsurg.2002.12.015)

15 Ojomo KA, Schneider DF, Reither AE, Lai N, Schaefer S, Chen H & Sippel RS. Using body mass index to predict optimal thyroid dosing after thyroidectomy. *Journal of the American College of Surgeons* 2013 216 454–460. (doi:10.1016/j.jamcollsurg.2012.12.002)

16 Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A & Corsello SM. A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. *Thyroid* 2014 24 1759–1764. (doi:10.1089/thy.2014.0111)

17 Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. *Nature Reviews. Endocrinology* 2014 10 164–174. (doi:10.1038/nrendo.2013.258)

18 Pepper GM & Casanova-Romero PY. Conversion to Armour thyroid hormone replacement. *Journal of Endocrinology, Diabetes & Obesity* 2013 2 1055–1060.

19 Gullo D, Latina A, Frasca F, Le Moil R, Pellegatti G & Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. *Plas ONE* 2011 6 e22552. (doi:10.1371/journal.pone.0022552)

20 Hoermann R, Midgley JEM, Larisch R & Dietrich JW. Is pituitary TSH an adequate measure of thyroid hormone-controlled homeostasis during thyroxine treatment? *European Journal of Endocrinology* 2013 168 271–280. (doi:10.1530/EJE-12-0819)

21 Midgley JEM, Hoermann R, Larisch R & Dietrich JW. Physiological states and functional relation between thyrotropin and free thyroxine in thyroid health and disease: in vivo and in silico data suggest a hierarchical model. *Journal of Clinical Pathology* 2013 66 335–342. (doi:10.1136/jclinpath-2012-201918)

22 Hoermann R, Midgley JEM, Giacobino A, Eckl WA, Wahl HG, Dietrich JW & Larisch R. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment. *Clinical Endocrinology* 2014 81 907–915. (doi:10.1111/cen.12527)

23 Larisch R, Giacobino A, Eckl W, Wahl HG, Midgley JEM & Hoermann R. Reference range for thyrotropin. Post hoc assessment. *Nuklearmedizin* 2015 54 112–117. (doi:10.3413/Nukmed-0671-1406)

24 Dietrich JW, Landgrafe G & Fotiadou EH. TSH and thyrotropic agonists: key actors in thyroid homeostasis. *Journal of Thyroid Research* 2012 2012 1–29. (doi:10.1155/2012/351864)

25 Fellows I. Deducer: a data analysis GUI for R. *Journal of Statistical Software* 2012 49 1–15.

26 Core Team, R: A Language and Environment for Statistical Computing. *R Foundation for Statistical Computing* 2014. Vienna, Austria: R Foundation for Statistical Computing. (available at: http://www.R-project.org/)

27 Silva EJ, Gordon MR, Crantz FR, Leonard JL & Larsen PR. Qualitative and quantitative differences in the pathways of extrathyroidal triiodothyronine generation between euthyroid and hypothyroid rats. *Journal of Clinical Investigation* 1984 73 898–907. (doi:10.1172/JCI111313)

28 Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla SM, Wittmann G, Lechan RM, Gereben B & Bianco AC. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. *Journal of Clinical Investigation* 2015 125 769–781. (doi:10.1172/jci77588)

29 Herriot R, McKinlay AW, Bevan JS & Abraham P. Factors contributing to thyrotropin levels in untreated hypothyroid patients. *Journal of Clinical Endocrinology and Metabolism* 2009 94 426–430. (doi:10.1148/ j.1365-2265.2008.03940.x)

30 Cettour-Rose P, Visser TJ, Burger AG & Rohner-Jeanrenaud F. Inhibition of pituitary type 2 deiodinase by reverse triiodothyronine does not alter thyroxine-induced inhibition of thyrotropin secretion in hypothyroid rats. *European Journal of Endocrinology* 2005 153 429–434. (doi:10.1016/j.ejcn.1998)

31 Toft Kristensen T, Larsen J, Pedersen PL, Feldthusen A-D, Ellervik C, Ford I, Højrup P, Laskarz E, Madsen M, Nørgaard M et al. Guidelines for the diagnosis and monitoring of thyroid disease. *Journal of Clinical Endocrinology and Metabolism* 2005 90 124–127. (doi:10.1210/jc.2004-1306)

32 Liwanpo L & Hershman JM. Conditions and drugs interfering with thyroid absorption. *Best Practice & Research. Clinical. Endocrinology and Metabolism* 2009 23 781–792. (doi:10.1016/j.beem.2009.06.006)

33 Robertson HMA, Narayanaswamy AKP, Pereira O, Copland SA, Herriot R, McKinlay AW, Bevan JS & Abraham P. Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. *Thyroid* 2014 24 1765–1771. (doi:10.1089/thy.2013.0661)

34 Toft Kristensen T, Larsen J, Pedersen PL, Feldthusen A-D, Ellervik C, Jelstrup S & Kvetny J. Weight gain and serum TSH increase within the first 2 years of replacement therapy. *Clinical Endocrinology* 2013 176 1–9. (doi:10.1111/j.1365-2265.2012.04131.x)

35 Robertson HMA, Narayanaswamy AKP, Pereira O, Copland SA, Herriot R, McKinlay AW, Bevan JS & Abraham P. Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. *Thyroid* 2014 24 1765–1771. (doi:10.1089/thy.2013.0661)

36 Banovac K, Carrington SA, Levis S, Fill MD & Bilker MS. Determination of replacement and suppressive doses of thyroxine. *Journal of International Medical Research* 1990 18 210–218.
37 Gordon MB & Gordon MS. Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocrine Practice 1999 5 233–238. (doi:10.4158/EP.5.5.233)

38 Baehr KM, Lyden E, Treude K, Erickson J & Goldner W. Levothyroxine dose following thyroidectomy is affected by more than just body weight. Laryngoscope 2012 122 834–838. (doi:10.1002/lary.23186)

39 de Lima JG, de Mesquita DJTM, da Costa Fernandes F, de Souza ABC, Santos Junior dos AC, Reboucas B, de Lima NN, Sousa AGP & Nobrega LHC. Comparison among the daily levothyroxine doses according to the etiology of hypothyroidism. Journal of Endocrinology and Metabolism 2013 3 1–6. (doi:10.4021/jem165w)

40 Abdalla SM & Bianco AC. Defending plasma T3 is a biological priority. Clinical Endocrinology 2014 81 633–641. (doi:10.1111/cen.12538)

41 Fonseca TL, Correa-Medina M, Campos MPO, Wittmann G, Werneck-de-Castro JP, Arrojo e Drigo R, Mora-Garzon M, Ueta CB, Caicedo A, Fekete C et al. Coordination of hypothalamic and pituitary T3 production regulates TSH expression. Journal of Clinical Investigation 2013 123 1492–1500. (doi:10.1172/JCI61231)

42 Hoftijzer HC, Heemstra KA, Visser TJ, de Cessie S, Peeters RP, Corssmit EPM & Smit JWA. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus–pituitary–thyroid axis in patients treated for differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2011 96 E1527–E1533. (doi:10.1210/jc.2011-0235)

43 Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Fraying TM & Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1623–1629. (doi:10.1210/jc.2008-1301)

44 Taylor PN, Panicker V, Sayers A, Shields B, Iqbal A, Bremner AP, Beilby JP, Leedman PJ, Hattersley AT, Vaidya B et al. A meta-analysis of the associations between common variation in the PDE8B gene and thyroid hormone parameters, including assessment of longitudinal stability of associations over time and effect of thyroid hormone replacement. European Journal of Endocrinology 2011 164 773–780. (doi:10.1530/EJE-10-0938)

45 McAninch EA, Jo S, Preite NZ, Farkas E, Mohácsik P, Fekete C, Egri P, Gereben B, Li Y, eng Y et al. Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. Journal of Clinical Endocrinology and Metabolism 2015 100 920–933. (doi:10.1210/jc.2014-4092)

46 Wiersinga WM. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism? European Journal of Endocrinology 2009 161 955–959. (doi:10.1530/EJE-09-0879)

47 Wiersinga WM, Duntas L, Fadeyev V, Nygaard B & Vanderpump MPJ. ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. European Thyroid Journal 2012 1 55–71. (doi:10.1159/000339444)

48 Watt T, Cramong P, Hegedus L, Bjorner JB, Bonnema SJ, Rasmussen ÅK, Feldt-Rasmussen U & Groenvold M. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. Journal of Clinical Endocrinology and Metabolism 2014 99 3708–3717. (doi:10.1210/jc.2014-1322)

Received in final form 10 August 2015
Accepted 11 August 2015